Nurix Therapeutics price target lowered to $27 from $35 at BTIG

BTIG lowered the firm’s price target on Nurix Therapeutics (NRIX) to $27 from $35 and keeps a Buy rating on the shares. The firm cites the company having detailed their pivotal plans for bexobrutideg in r/r CLL – Relapsed or Refractory Chronic Lymphocytic Leukemia – and announced a concurrent raise of $250M, noting that the raise clears a financing overhang for the stock and providing a line of sight to key data catalysts and accelerating bexdeg’s I&I expansion, the analyst tells investors in a research note.